Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH - Slideshow

SA Transcripts157.42K FollowersFollow5ShareSaveCommentsThe following slide deck was published by Altimmune, Inc. in conjunction with this event. This article was written bySA Transcripts157.42K FollowersFollowSeeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team